BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 25, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
June 20, 2016
View Archived Issues
Renaissance topical division sold to Mylan
Read More
Kyushu University and Nippon Chemiphar begin phase I trial for NC-2600
Read More
MTD for PQR-309 determined in patients with advanced solid tumors
Read More
Phase II results for TRC-105 plus bevacizumab in patients with bevacizumab-refractory glioblastoma
Read More
Phase II results for CDX-1401 in patients with malignant melanoma pretreated with CDX-301
Read More
Boehringer Ingelheim discloses aldosterone synthase inhibitors
Read More
The Meghan Rose Bradley Foundation supports VBI Vaccines' immunotherapy research
Read More
Delta-Fly Pharma patents drug conjugates to treat cancer
Read More
C&C Research Laboratories announces STAT3 inhibitors
Read More
Actelion Pharmaceuticals divulges chemokine receptor agonists
Read More
Cerus enters into agreement with BARDA for INTERCEPT funding
Read More
Grunenthal reports TRPV1 ligands
Read More
The Medicines Co. presents new beta-lactamase inhibitors
Read More
Poxel advances phase I trial of direct AMPK activator PXL-770
Read More
Orbus Therapeutics' brain cancer drug receives EMA orphan medicinal product status
Read More
GSK's FULFIL study of closed triple combination therapy for COPD meets co-primary endpoints
Read More
TiGenix reports phase I/II results on AlloCSC-01
Read More
Orphazyme begins dosing patients in phase III AIDNPC interventional study
Read More
Circassia's phase III cat allergy study fails to meet primary endpoint
Read More
Japan Tobacco receives Japanese manufacturing and marketing approval for Genvoya
Read More
ARIAD Pharmaceuticals begins rolling NDA submission for brigatinib
Read More
Safety and pharmacokinetics of anti-IL-17 MAb assessed in phase I study
Read More
Phase II expansion investigates savolitinib with osimertinib for advanced EGFR-mutant NSCLC
Read More
MEDI-3902 combined with tobramycin shows promise in an acute pneumonia model
Read More
Summit Therapeutics enrolls first patient in Phaseout DMD study
Read More
FDA grants EUA to Hologic's Aptima Zika Virus assay
Read More
Roche's LightMix Modular Zika Virus Assay now available
Read More
Blade Therapeutics closes series B financing
Read More